Comparison of the PCFS Scale and 6MWT end Borg rating according to the type of sequelae
| Type of sequelae | P value | |||
| No pulmonary sequelae, n=27 | Isolated dyspnoea, n=41 | Pulmonary sequelae, n=53 | Between three groups* | |
| PCFS Scale (mean±SD) | 0.6±0.8 | 1.7±1 | 1.3±1.1 | <0.001 |
| 6MWT end Borg rating (mean±SD) | 2.6±1.2 | 5.2±2.3 | 3.4±2.6 | 0.001 |
Isolated dyspnoea: patients who described remaining dyspnoea with no chest CT scan or TLco abnormalities. Pulmonary sequelae: patients who had at least a chest CT scan abnormality or TLco impairment, with or without associated dyspnoea (see online supplemental table 3).
*There was a significant difference between the PCFS Scale in the three groups. PCFS Scale and 6MWT end Borg rating results were then compared according to the type of described sequelae. Significant differences were observed between each group (p<0.05), except for the mean 6MWT end Borg rating in the no pulmonary sequelae and the pulmonary sequelae groups.
6MWT, Six-Minute Walk Test; PCFS, Post-COVID-19 Functional Status; TLco, carbon monoxide transfer factor.